CYP3A4 and graft versus host disease: For GvHD patients, a reduced RUX starting dose of 5 mg BID is only recommended if it is co-administered with fluconazole, whereas dose adjustments when used concomitantly with strong CYP3A4 inhibitors are explicitly excluded.